DV
Dividend Vision

RARE — Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc. (RARE)

Total return is -37.3% over the past 12.5 years, 475.1 points behind SPY at 437.8%. Its deepest 1-year drawdown was 49.4%.

This is a single-stock equity holding in Ultragenyx Pharmaceutical Inc., a biotechnology company focused on rare genetic diseases, rather than a diversified ETF with a defined dividend strategy. The holding does not currently pay distributions and has no associated expense ratio or yield profile typical of income-focused ETF products. This security structure appeals primarily to equity investors seeking exposure to a specific pharmaceutical company rather than dividend or income-focused investors.

RARE key facts

Asset type
Stock
Asset class
Equity
Inception date
01/31/2014
Distribution frequency
None
Last close
$26.49
Market cap
$2,611,619,072
Average volume
1220700.0
Beta
0.313
Payout ratio
0.0
Forward P/E
0.0
EPS
$-5.83